NCT05857163 - Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection | Biotech Hunter

Enrollment

700

Participants

Timeline

Start Date

May 18, 2023

Primary Completion Date

December 24, 2023

Study Completion Date

March 26, 2024

Conditions

H.Pylori Infection

Interventions

DRUG

Rifasutenizol capsules

400 mg, BID, taken orally within half an hour after breakfast and dinner.

DRUG

Rabeprazole sodium enteric-coated tablets

20 mg, BID, taken orally within half an hour before breakfast and dinner.

DRUG

Amoxicillin Capsules

1 g, BID, taken orally within half an hour after breakfast and dinner.

DRUG

Clarithromycin placebo tablets

BID, taken orally within half an hour after breakfast and dinner.

DRUG

Bismuth potassium citrate placebo capsules

BID, taken orally within half an hour before breakfast and dinner.

DRUG

Clarithromycin tablets

500 mg, BID, taken orally within half an hour after breakfast and dinner.

DRUG

Bismuth potassium citrate capsules

240 mg, BID, taken orally within half an hour before breakfast and dinner.

DRUG

Rifasutenizol placebo capsules

BID, taken orally within half an hour before breakfast and dinner.

Trial Locations (1)

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

TenNor Therapeutics (Suzhou) Limited

INDUSTRY